FLT3 and acute lymphoblastic leukemia: Mehta et al. developed a bispecific antibody IgG, CLN-049, directed against FLT3 and CD3, targeting AML and B-ALL in a mouse xenograft model, regardless of FLT3 mutation [54], sparing normal hematopoietic cells, making it a possible candidate in future studies.